NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
28/05/2024
Voltar para busca
Dado oficial do USPTO
SYNER-G BIOPHARMA GROUP
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
28/05/2024
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
35, 42, 45
Data de depósito
16/09/2021
Data de registro
28/05/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
28/05/2024
Última transação
28/05/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
20/10/2021
Primeiro uso no comércio
20/10/2021
Código do desenho
3
Tipo de titular
16
Localização do titular
Framingham, MA, US
Examinador
GAYNOR, BARBARA ANNE
Unidade examinadora
M60
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a stylized pyramid with one side consisting of a solid triangle and the other side consisting of lines forming a triangle appearing to the left of the stylized word "SYNER-G" above the stylized words "BioPharma Group" with the words separated by a horizontal line.
Titulares e representantes
Titulares
SYNER-G BIOPHARMA GROUP LLC
SYNER-G BIOPHARMA GROUP LLC
Syner-G Pharma Consulting, LLC
Representantes
Sara M. Bauer Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 35Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 35
Providing business intelligence services in the fields of pharmaceuticals, biotechnology, and life sciences; business consulting services in the fields of pharmaceuticals and biopharmaceuticals and related technologies, specifically, business consulting with respect to clinical development, formulation, evaluation, approval, delivery, commercialization, marketing, and life-cycle management of drugs; business services, namely, formulation of best practices for drug discovery, formulation development, clinical supplies, pharmacology, toxicology, clinical supplies, and clinical development services; regulatory submission management, namely, assisting others in preparing and filing applications for new pharmaceuticals with governmental regulatory bodies
Classe 42
Consulting services in the fields of pharmaceutical research and development, biotechnology, and life sciences; providing scientific research services in the fields of pharmaceutical design and development, pharmaceutical chemistry, pharmaceutical manufacturing and controls; consulting services regarding research and development, pharmaceutical drug formulation development, and quality control for others in the fields of pharmaceuticals, biotechnology, and life sciences; technical advisory services in the fields of pharmaceutical research and development, biotechnology, and life sciences; technical consulting in the fields of pharmaceutical research and development, biotechnology, and life sciences; technical consulting services, namely, evaluating the safety of pharmaceutical products in clinical development or in commercial production; consultation services relating to consumer software in the fields of pharmaceuticals, biotechnology, and life sciences; Consulting services for others in the field of design, planning, and implementation project management of clinical trial development and clinical trials; Providing technical consulting services in the nature of advising on the testing, analysis and evaluation of the goods of others to determine conformity with certification standards; design and development of computer software for database management in the fields of pharmaceuticals, biotechnology and life sciences; pharmaceutical drug development services; toxicology services; Scientific research consulting in the field of clinical trial development and clinical trials
Classe 45
Regulatory compliance consulting in the fields of pharmaceuticals, biotechnology, and life sciences
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
28/05/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
24/04/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
24/04/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
20/04/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
20/04/2024
IUAF
USE AMENDMENT FILED
02/04/2024
EISU
TEAS STATEMENT OF USE RECEIVED
02/04/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/10/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/10/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/10/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/10/2023
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/10/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/08/2023
PUBO
PUBLISHED FOR OPPOSITION
08/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
19/07/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/07/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/01/2023
GNSL
LETTER OF SUSPENSION E-MAILED
03/01/2023
CNSL
SUSPENSION LETTER WRITTEN
03/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/12/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/06/2022
GNRT
NON-FINAL ACTION E-MAILED
21/06/2022
CNRT
NON-FINAL ACTION WRITTEN
21/06/2022
DOCK
ASSIGNED TO EXAMINER
21/06/2022
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/06/2022
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
22/10/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
21/10/2021
NWAP
NEW APPLICATION ENTERED
20/09/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYNER-G BIOPHARMA GROUP ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.